EVALUATING IMMUNE COMPETENCE

• US 20090062237A1
• Filed: 06/13/2008
• Published: 03/05/2009
• Est. Priority Date: 06/15/2007
• Status: Abandoned Application

• Current Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Original Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Inventors: Nandakumar, Vijay, Abraham, Roshini Sarah
• Application Number:
  US12/139,115
• Publication Number:
  US 20090062237A1
• Time in Patent Office: Days
• US Class Current: 514/86
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2710/22022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

This document relates to methods and materials involved in evaluating immune competence in a subject. For example, methods and materials for evaluating immune competence in a subject to BK virus (BKV) are provided. Also provided are isolated peptides, compositions, and methods useful for evaluating whether or not a subject is BKV immunocompetent. Also provided are methods for treating BK virus nephropathy in a subject that is BKV immune incompetent.

Claims

1. An isolated peptide selected from the group consisting of SEQ ID NOS:

1-107, SEQ ID NOS;

109-258, and SEQ ID NOS;

260-373.

2. A composition comprising an MHC molecule and a peptide selected from the group consisting of SEQ ID NOS:

1-107, SEQ ID NOS;

109-258, and SEQ ID NOS;

260-373.

3. The composition of claim 2, wherein said MHC molecule is selected from the group consisting of HLA-B7, HLA-A1, and HLA-A2.

4. The composition of claim 2, wherein said MHC molecule is selected from the group consisting of HLA-B8 and HLA-B35.

5. The composition of claim 2, wherein said peptide is selected from the group consisting of SEQ ID NO:

342, SEQ ID NO;

252, SEQ ID NO;

2, SEQ ID NO;

80, SEQ ID NO;

14, and SEQ ID NO;

182.

6. A composition comprising an MHC molecule and a peptide selected from the group consisting of SEQ ID NOS:

1-373, wherein said MHC molecule is selected from the group consisting of HLA-B7 and HLA-A1.

7. A composition comprising an MHC/peptide multimer and a peptide selected from the group consisting of SEQ ID NOS:

1-373.

8. The composition of claim 7, wherein said MHC molecule is selected from the group consisting of HLA-B7, HLA-A1, and HLA-A2.

9. The composition of claim 7, wherein said MHC molecule is selected from the group consisting of HLA-B8 and HLA-B35.

10. The composition of claim 7, wherein said peptide is selected from the group consisting of SEQ ID NO:

342, SEQ ID NO;

252, SEQ ID NO;

2, SEQ ID NO;

80, SEQ ID NO;

14, SEQ ID NO;

182, SEQ ID NO;

108, and SEQ ID NO;

259.

11. The composition of claim 7, wherein said composition comprises more than one different peptide.

12. The composition of claim 11, wherein said composition comprises 2 different peptides.

13. The composition of claim 11, wherein the composition comprises 3 different peptides.

14. The composition of claim 11, wherein the composition comprises 4 different peptides.

15. The composition of claim 11, wherein the composition comprises more than 4 different peptides.

16. A kit comprising a peptide selected from the group consisting of SEQ ID NOS:

1-373 and an antibody selected from the group consisting of anti-interferon-gamma, anti-TNF-alpha, anti-IL-2, anti-CD107a, and anti-CD107b.

17. A method of evaluating whether or not a subject is BK Virus immunocompetent, comprising contacting CD8+ T cells from said subject with a composition comprising a peptide selected from the group consisting of SEQ ID NOS:

1-373, and evaluating one or more of said subject'"'"'s BK Virus-specific CD8+ T cell parameters as compared to the minimum BK Virus-specific CD8+ T cell parameters required for BK Virus immunocompetence.

18. The method of claim 17, wherein said peptide is part of an MHC/peptide complex.

19. The method of claim 17, wherein said peptide is part of an MHC/peptide multimer.

20. The method of claim 19, wherein said evaluating comprises performing flow cytometry.

21. The method of claim 19, wherein said evaluating comprises performing an ELISA-based assay.

22. A method of treating BK Virus nephropathy in a transplant patient comprising evaluating whether said patient is BK Virus immunocompetent or immune incompetent, and administering an appropriate dose of an immunosuppressive drug.

23. The method of claim 22, wherein said immunosuppressive drug is tacrolimus.

24. The method of claim 22, wherein said immunosuppressive drug is rapamycin.

25. A method of treating BK Virus nephropathy in a transplant patient comprising determining whether said patient is BK Virus immune incompetent, and based on said determination of immunodeficiency, administering an appropriate dose of an antiviral drug.

26. The method of claim 25, wherein said antiviral drug is cidifovir.